Skip to main content

Table 1 Cohort demographics and clinical data

From: Circulating brain-enriched microRNAs as novel biomarkers for detection and differentiation of neurodegenerative diseases

Diagnosis Subgroups No. of subjects Age (years) Sex (M/F) MMSE [NR] CSF Aβ42 CSF t-tau CSF p-tau Years from diagnosis Years of education
Control N/A 50 64.06 ± 9.8 (25–83) 24/26 29.3 ± 1.0 N/A N/A N/A N/A 16.44 ± 2.7
AD N/A 50 67.8 ± 10.4 (53–87) 24/26 21.0 ± 5.6 145.7 ± 34.8 116.2 ± 68 45 ± 23.7 3.6 ± 2.2 16.5 ± 2.3
PD Total 50 66.76 ± 7.7 (49–82) 35/15 28.9 ± 1.1 [11] 261.8 ± 49.8 43 ± 13.7 20.9 ± 7.4 10 ± 5.1 16.54 ± 2.2
Dementia 15 72.33 ± 6.1 (61–82) 11/4 27 [1] N/A N/A N/A 11 ± 3.9 16.33 ± 2.8
MCI 8 68.37 ± 7.0 (54–77) 5/3 29 ± 0.8 [4] N/A N/A N/A 10.4 ± 7.4 16.25 ± 1.7
FTD Total 50 63.14 ± 6.9 (46–76) 28/22 24.1 ± 5.3 [46] 271.4 ± 52.3 62.2 ± 27.9 16.5 ± 7.8 3.2 ± 2.3 15.96 ± 3.1
bv 23 61.69 ± 6.3 (46–74) 15/8 25.3 ± 4.4 278.6 ± 52.3 57.2 ± 22.5 14.5 ± 4.6 2.7 ± 2.2 16.43 ± 3.0
PPA/Lgpen 1 70 1/0 22     2 18
PPA/PNFA 8 67.75 ± 4.6 (61–75) 3/5 19.6 ± 9.18 [5] 269.9 ± 63.5 75.2 ± 35.2 14.6 ± 4.3 4.5 ± 2.1 15.2 ± 3.84
PPA/SD 8 61.25 ± 8.4 (49–76) 4/4 22.1 ± 5.19 286 ± 48.4 79.9 ± 36.6 15.9 ± 4.5 4 ± 3.0 17 ± 2.82
PSP 10 63.6 ± 7.51 (54–75) 5/5 25.6 ± 4.4 244.7 ± 46.0 50.6 ± 19.5 14.5 ± 4.6 2.7 ± 1.6 14.4 ± 2.99
ALS Total 50 59.64 ± 10.8 (29–83) 36/14 24.8 ± 7.8 [16] 240.4 ± 76.3 71.1 ± 50.7 13.8 ± 6.8 1.8 ± 1.8 14.71 ± 2.9
With FTD 5 65.4 ± 9.18 (49–70) 4/1 14. 3 ± 12.0 [3] 222.4 ± 88.8 107 ± 62.1 19 ± 10.1 4 ± 4.4 15.8 ± 2.3
With MCI 3 57 ± 5.2 (54–63) 2/1 30 [1] 340 ± 3 66 ± 32 11.3 ± 0.6 1 ± 1 13.5 ± 7.8
  1. Abbreviations: Aβ 42 Amyloid-β 42, AD Alzheimer’s disease, ALS Amyotrophic lateral sclerosis, FTD Frontotemporal dementia, PD Parkinson’s disease, M/F Male/female, MMSE Mini Mental State Examination, NR Number of research participants with Mini Mental State Examination reported (MMSE is reported for all participants in a subgroup [e.g., control] if no NR value is given), N/A Not available, bv Behavioral variant, PPA/Lgpen Primary progressive aphasia, logopenic variant, PPA/PNFA Primary progressive aphasia/progressive nonfluent aphasia, PPA/SD Primary progressive aphasia/semantic dementia, PSP Progressive supranuclear palsy, CSF Cerebrospinal fluid, MCI Mild cognitive impairment, p-tau Phosphorylated tau, t-tau Total tau